Sector: MedicalARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 209 |
Technical : | 19 |
Performance : | 143 |
Overall: | 111 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 221 |
Technical : | 249 |
Performance : | 256 |
Overall: | 284 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 215 |
Technical : | 198 |
Performance : | 250 |
Overall: | 271 |
Number of Stocks: | 306 |
Headlines
- Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks
Nov 11, 2009 10:44 AM | ARIA, BBI, BMRN, BMY, CELG, IMGN
- ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Nov 10, 2009 07:35 AM | ARIA
- ARIAD Reports Third Quarter 2009 Development Progress and Financial Results
Nov 05, 2009 07:35 AM | ARIA
- ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
Nov 02, 2009 12:00 PM | ARIA
- ARIAD to Present at the Oppenheimer 20th Annual Healthcare Conference
Oct 27, 2009 07:35 AM | ARIA
- ARIAD to Webcast Conference Call on Third Quarter 2009 Financial Results
Oct 22, 2009 07:34 AM | ARIA
- ARIAD Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab
Sep 21, 2009 07:35 AM | ARIA
- Market Closing: Stocks Manage Narrowly Higher Finish Thanks To Late Move
Sep 14, 2009 04:30 PM | ARIA, CWTR, DAL, ETFC, GT, LVS
- Stocks Look to Start Under Water - China-U.S. Trade Spat Lifts Dollar, Pressures Commodities
Sep 14, 2009 09:20 AM | ARIA, CORS, ETFC, S
- ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas
Sep 14, 2009 07:35 AM | ARIA
- PicksThatMove.Com Announces Investment Opinion: Small Cap Biopharmaceuticals and Biotechnology 101 From PicksThatMove
Sep 15, 2009 05:51 PM | ARIA, DSCO, KERX, THC
- ARIAD Announces Completion of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
Aug 07, 2009 10:51 AM | ARIA, MRK
- Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
Aug 06, 2009 08:01 AM | ARIA
- ARIAD Prices Public Offering of Common Stock
Aug 04, 2009 09:56 AM | ARIA
- ARIAD Announces Proposed Public Offering of Common Stock
Aug 03, 2009 04:08 PM | ARIA
- Ariad Reports Second Quarter 2009 Financial Results and Development Progress
Jul 30, 2009 04:12 PM | ARIA
- ARIAD Announces Preliminary Data from Two Ongoing Clinical Trials of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Targeted Drugs
Jul 28, 2009 07:32 AM | ARIA
- ARIAD to Webcast Conference Call on Second Quarter 2009 Financial Results and Clinical Data Released Today
Jul 27, 2009 07:36 AM | ARIA
- ARIAD Announces Preliminary Results from Ongoing Clinical Trial of Its Investigational, Bcr-Abl Inhibitor – AP24534 – in Drug-Resistant Chronic Myeloid Leukemia
Jul 27, 2009 07:33 AM | ARIA
- ARIAD Announces Webcast of Its Annual Stockholders Meeting
Jun 08, 2009 07:36 AM | ARIA
- Form 4 IULIUCCI JOHN D For: Oct 01 (10K)
Oct 05, 2009 06:10 PM
- Form 4 BERGER HARVEY J M D For: Aug 04 (10K)
Aug 06, 2009 06:05 PM
- Form 4 DODION PIERRE F For: Aug 04 (10K)
Aug 06, 2009 06:04 PM
- Form 3 Ros Matthew E For: Apr 03 (10K)
Apr 10, 2009 05:57 PM
- Form 3 Bollag Daniel M For: Apr 03 (10K)
Apr 10, 2009 05:57 PM
- Form 4 WILSON WAYNE For: Apr 03 (10K)
Apr 07, 2009 05:56 PM
- Form 4 LAMARCHE JAY R For: Apr 03 (10K)
Apr 07, 2009 05:55 PM
- Form 4 Radaelli Massimo For: Apr 03 (10K)
Apr 07, 2009 05:54 PM
- Form 4 Smyth A. Collier For: Apr 03 (10K)
Apr 07, 2009 05:54 PM
- Form 4 LAVIDAS ATHANESE For: Apr 03 (10K)
Apr 07, 2009 05:54 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ARIA
|
Compare to S&P
|
| YTD |
154.12 %
|
110.31 %
|
| 4 Weeks |
6.93 %
|
5.78 %
|
| 12 Weeks |
-2.26 %
|
-7.86 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 12.50 %
|
|
EPS Growth in Last Year: 27.59 %
|
|
Sales Growth in Last Quarter: 2.91 %
|
|
Sales Growth in Last Quarter: 40.30 %
|
|
